Palbocent
Generic Name
Palbociclib
Manufacturer
Reputable Pharmaceutical Co.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| palbocent 125 mg capsule | ৳ 400.00 | ৳ 2,800.00 |
Description
Overview of the medicine
Palbocent 125 mg capsule contains Palbociclib, an oral cyclin-dependent kinase (CDK) 4 and 6 inhibitor. It is used in combination with an aromatase inhibitor or fulvestrant for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Uses & Indications
Dosage
Adults
125 mg orally once daily for 21 consecutive days, followed by 7 days off treatment (28-day cycle). Take with food. Continue treatment as long as the patient is benefiting from therapy.
Elderly
No specific dose adjustment is required based on age.
Renal_impairment
No dose adjustment needed for mild or moderate renal impairment. For severe renal impairment (CrCl < 30 mL/min), a reduced dose may be considered.
How to Take
Take orally once daily with food, preferably around the same time each day. Swallow the capsule whole; do not chew, crush, or open.
Mechanism of Action
Palbociclib is a highly selective, reversible inhibitor of cyclin-dependent kinases (CDK) 4 and 6. By inhibiting CDK4/6, palbociclib prevents cell cycle progression from G1 to S phase, thereby reducing cancer cell proliferation.
Pharmacokinetics
Onset
Not immediately applicable, refers to anti-cancer effect over time.
Excretion
Primarily via feces (74%), with a smaller amount excreted in urine (17%).
Half life
Approximately 25.8 hours.
Absorption
Well absorbed after oral administration, peak plasma concentrations reached in 6-12 hours. High-fat food increases exposure.
Metabolism
Primarily metabolized by CYP3A and SULT2A1, with extensive first-pass metabolism.
Side Effects
Contraindications
- •Patients with a known hypersensitivity to palbociclib or any component of the formulation.
- •Pregnancy and breastfeeding.
Drug Interactions
CYP3A substrates (e.g., midazolam, everolimus, sirolimus)
Palbociclib may increase concentrations of co-administered CYP3A substrates.
Strong CYP3A inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's wort)
May significantly decrease palbociclib exposure; avoid concomitant use.
Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, grapefruit juice)
May significantly increase palbociclib exposure; avoid concomitant use or reduce palbociclib dose.
Storage
Store at room temperature (20°C to 25°C), away from moisture and light. Keep out of reach of children.
Overdose
There is no known antidote for palbociclib overdose. Treatment should involve general supportive measures.
Pregnancy & Lactation
Not recommended during pregnancy due to potential fetal harm. Women of reproductive potential should use effective contraception during treatment and for at least 3 weeks after the last dose. Men should use effective contraception for at least 3 months after the last dose. Not recommended during breastfeeding due to potential harm to the infant; advise women not to breastfeed during treatment and for 3 weeks after the last dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 months.
Availability
Hospitals, specialized oncology pharmacies
Approval Status
Approved (FDA approved)
Patent Status
Patent protected (original compound)
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in